The Tumor Profiler Study is an observational clinical study combining a prospective diagnostic approach to assess the relevance of in-depth tumor profiling to support clinical decision-making ("Fast Diagnostic loop") with an exploratory approach to improve the biological understanding of disease ("Exploratory science loop").
For this study of melanoma, ovarian carcinoma, and acute myeloid leukemia tumors, in addition to the emerging standard diagnostic approaches of targeted NGS panel sequencing and digital pathology, extensive characterization is performed using the following exploratory technologies: single-cell genomics and transcriptomics, proteotyping, CyTOF, imaging CyTOF, pharmacoscopy, and 4i drug response profiling (4i DRP).
[
Irmisch et al., Cancer Cell, 2021]
Commentary published in Cancer Cell
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
Posted on January 21, 2021
The application and integration of molecular profiling technologies create novel opportunities for personalized medicine. Here, we introduce the Tumor Profiler Study, an observational trial combining a prospective diagnostic approach to assess the relevance of in-depth tumor profiling to support clinical decision-making with an exploratory approach to improve the biological understanding...
[Read More]
Final melanoma Pre-TB
The goal of 120 participants enrolled in the melanoma arm of the study reached
Posted on December 7, 2020
Today, the last Pre-Tumor Board (Pre-TB) in the melanoma arm of the Tumor Profiler Study took place at the University Hospital Zurich.
[Read More]
